Paper32106643
Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
Han MR and 6 others. Cancer Res Treat, 2020. Cited by 40 papers, by iCite.
Cite this record
ConductScience Library. Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer. Papers, record 32106643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32106643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical Implications of Circulating Tumor DNA from Ascites and Serial Plasma in Ovarian Cancer.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Ascites | Major topic |
| Biomarkers, Tumor | Major topic |
| Circulating Tumor DNA | Major topic |
| Mutation | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Ovarian Neoplasms | Major topic |
| Plasma | Major topic |
| Adenocarcinoma, Clear Cell | |
| Adult | |
| Cystadenocarcinoma, Serous | |
| Female | |
| Follow-Up Studies | |
| High-Throughput Nucleotide Sequencing | |
| Humans | |
| Longitudinal Studies | |
| Middle Aged | |
| Prognosis | |
| Survival Rate |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| Incheon National University | PubMed | |||
| 2016R1D1A1B04932862 | National Research Foundation of Korea | PubMed |
Source PubMed
References28
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26633127 | SIFT missense predictions for genomes. | Nat Protoc | 2016 | https://conductscience.org/library/papers/26633127 | PubMed |
| 2 | 19587342 | Clinical practice. Screening for ovarian cancer. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19587342 | PubMed |
| 3 | 24767708 | Ovarian cancer. | Lancet | 2014 | https://conductscience.org/library/papers/24767708 | PubMed |
| 4 | 29348365 | Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Science | 2018 | https://conductscience.org/library/papers/29348365 | PubMed |
| 5 | 28468865 | Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. | Mol Cancer Ther | 2017 | https://conductscience.org/library/papers/28468865 | PubMed |
| 6 | 15837735 | Frequent mutation of the PIK3CA gene in ovarian and breast cancers. | Clin Cancer Res | 2005 | https://conductscience.org/library/papers/15837735 | PubMed |
| 7 | 27741368 | Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling. | J Pathol | 2017 | https://conductscience.org/library/papers/27741368 | PubMed |
| 8 | 30118648 | Next-generation sequencing reveals mutational accordance between cell-free DNA from plasma, malignant pleural effusion and ascites and directs targeted therapy in a gastric cancer patient. | Cancer Biol Ther | 2019 | https://conductscience.org/library/papers/30118648 | PubMed |
| 9 | 20601685 | ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. | Nucleic Acids Res | 2010 | https://conductscience.org/library/papers/20601685 | PubMed |
| 10 | 20166213 | Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. | Cancer | 2010 | https://conductscience.org/library/papers/20166213 | PubMed |
| 11 | 28233803 | Liquid biopsies come of age: towards implementation of circulating tumour DNA. | Nat Rev Cancer | 2017 | https://conductscience.org/library/papers/28233803 | PubMed |
| 12 | 30422115 | Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. | Elife | 2018 | https://conductscience.org/library/papers/30422115 | PubMed |
| 13 | 28655895 | Korean Variant Archive (KOVA): a reference database of genetic variations in the Korean population. | Sci Rep | 2017 | https://conductscience.org/library/papers/28655895 | PubMed |
| 14 | 26588231 | Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. | Int J Gynecol Cancer | 2016 | https://conductscience.org/library/papers/26588231 | PubMed |
| 15 | 23396013 | Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. | Nat Biotechnol | 2013 | https://conductscience.org/library/papers/23396013 | PubMed |
| 16 | 27997533 | Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study. | PLoS Med | 2016 | https://conductscience.org/library/papers/27997533 | PubMed |
| 17 | 30075112 | A Dominantly Inherited 5' UTR Variant Causing Methylation-Associated Silencing of BRCA1 as a Cause of Breast and Ovarian Cancer. | Am J Hum Genet | 2018 | https://conductscience.org/library/papers/30075112 | PubMed |
| 18 | 23563269 | Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. | Nature | 2013 | https://conductscience.org/library/papers/23563269 | PubMed |
| 19 | 30910306 | Epithelial ovarian cancer. | Lancet | 2019 | https://conductscience.org/library/papers/30910306 | PubMed |
| 20 | 25851949 | PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. | Bioinformatics | 2015 | https://conductscience.org/library/papers/25851949 | PubMed |
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42435174 | Cell-Free DNA (cfDNA), Its Applications in Cancer Diagnosis and Monitoring, and Its Potential Role in Regulating Cancer Metabolism. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435174 | PubMed |
| 41602395 | The role of circulating tumor DNA in gynecological cancer management. | Front Oncol | 2025 | https://conductscience.org/library/papers/41602395 | PubMed |
| 41363274 | Detecting TP53 mutations in paired liquid and tissue biopsies from patients with high-grade serous ovarian carcinoma. | Int J Cancer | 2026 | https://conductscience.org/library/papers/41363274 | PubMed |
| 41327898 | DNA-Based Liquid Biopsy for Evaluating Surgical and Postsurgical Outcomes in Gynecologic Malignancies: A Systematic Review. | J Clin Lab Anal | 2026 | https://conductscience.org/library/papers/41327898 | PubMed |
| 41088281 | Harnessing ovarian cancer ascites for translational science: models, biomarkers, and therapeutics. | Mol Cancer | 2025 | https://conductscience.org/library/papers/41088281 | PubMed |
| 40340939 | Liquid biopsy in gynecological cancers: a translational framework from molecular insights to precision oncology and clinical practice. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40340939 | PubMed |
| 40278372 | Cell-Free DNA (cfDNA) Regulates Metabolic Remodeling in the ES-2 Ovarian Carcinoma Cell Line, Influencing Cell Proliferation, Quiescence, and Chemoresistance in a Cell-of-Origin-Specific Manner. | Metabolites | 2025 | https://conductscience.org/library/papers/40278372 | PubMed |
| 40076521 | Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use? | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40076521 | PubMed |
| 40075633 | ctDNA as an Objective Marker for Postoperative Residual Disease in Primary Advanced High-Grade Serous Ovarian Cancer. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40075633 | PubMed |
| 40027149 | Liquid biopsy into the clinics: Current evidence and future perspectives. | J Liq Biopsy | 2024 | https://conductscience.org/library/papers/40027149 | PubMed |
| 39201516 | Phenotyping Tumor Heterogeneity through Proteogenomics: Study Models and Challenges. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39201516 | PubMed |
| 39115191 | Cell-free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer. | Mol Oncol | 2024 | https://conductscience.org/library/papers/39115191 | PubMed |
| 38966171 | Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities. | Explor Target Antitumor Ther | 2024 | https://conductscience.org/library/papers/38966171 | PubMed |
| 38417292 | Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial. | Transl Oncol | 2024 | https://conductscience.org/library/papers/38417292 | PubMed |
| 38392306 | Current Applications and Challenges of Next-Generation Sequencing in Plasma Circulating Tumour DNA of Ovarian Cancer. | Biology (Basel) | 2024 | https://conductscience.org/library/papers/38392306 | PubMed |
| 37932736 | Homologous recombination deficiency (HRD) testing on cell-free tumor DNA from peritoneal fluid. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37932736 | PubMed |
| 37707677 | Minimal residual disease in solid tumors: an overview. | Front Med | 2023 | https://conductscience.org/library/papers/37707677 | PubMed |
| 37700064 | The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review. | Br J Cancer | 2023 | https://conductscience.org/library/papers/37700064 | PubMed |
| 37479960 | Advances in application of circulating tumor DNA in ovarian cancer. | Funct Integr Genomics | 2023 | https://conductscience.org/library/papers/37479960 | PubMed |
| 37351260 | Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer. | Front Physiol | 2023 | https://conductscience.org/library/papers/37351260 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32106643
GET https://conductscience.org/api/papers/v1/32106643/references?page=2